Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in Gram-positive bacteria.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
FDA-approved: Treatment of respiratory tract infections, skin and soft tissue infections, bone and joint infections, septicemia, and urinary tract infections caused by susceptible organisms,Off-label: Prophylaxis in surgery, treatment of endocarditis
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
1-2 g IV every 4-6 hours; maximum 12 g/day.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
0.5-1 hour; prolonged in renal impairment (up to 8-12 hours in anuria)
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Cephalothin is metabolized in the liver by deacetylation to desacetylcephalothin, which has less antimicrobial activity. The enzyme responsible is not specifically identified but involves hepatic esterases.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal excretion (60-70% unchanged); biliary excretion (20-30%); fecal elimination (<1%)
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
65-80% bound to serum albumin
Low protein binding; 0–11% bound, primarily to albumin.
0.2-0.3 L/kg; primarily extracellular fluid
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%; intramuscular: approximately 50-60%
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
Cr Cl 50-80 m L/min: no adjustment; Cr Cl 25-50 m L/min: 1-2 g every 6-8 hours; Cr Cl 10-25 m L/min: 1-2 g every 8-12 hours; Cr Cl <10 m L/min: 1-2 g every 12-24 hours.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustment recommended; use caution in severe hepatic impairment.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
100-150 mg/kg/day IV divided every 6 hours; maximum 12 g/day.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
No specific adjustment; consider renal function and reduce dose if Cr Cl <50 m L/min.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams, including penicillins; anaphylaxis may occur,Pseudomembranous colitis: Clostridium difficile-associated diarrhea can develop,Renal impairment: Dosage adjustment required due to renal excretion; monitor renal function,Bleeding risk: May potentiate anticoagulants; monitor prothrombin time,False-positive urine glucose test: With Clinitest or Benedict's solution, but not with glucose oxidase methods
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypersensitivity to cephalothin, any cephalosporin, or other beta-lactam antibiotics,Absolute: Known anaphylactic reaction to penicillins due to cross-sensitivity
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No significant food interactions. Absorption is not affected by food. Avoid alcohol during treatment and for 72 hours after completion to prevent disulfiram-like reaction (reported with some cephalosporins, though rare with cephalothin).
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Cephalothin is a first-generation cephalosporin classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. However, systemic absorption is expected to be low with intraperitoneal administration. First trimester: No evidence of teratogenicity, but data limited. Second/third trimesters: Generally considered safe; cross the placenta with therapeutic concentrations achieved in fetal serum and amniotic fluid. No known association with congenital malformations.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Cephalothin is excreted into human breast milk in low concentrations. The milk-to-plasma ratio is approximately 0.02–0.05. For a maternal dose of 1 g intravenously, the estimated infant dose is <1% of the therapeutic dose. Considered compatible with breastfeeding but monitor infant for potential gastrointestinal effects (e.g., diarrhea, candidiasis) or allergic reactions.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may reduce serum cephalothin concentrations. However, no formal dosing adjustments are recommended; standard adult dosing is used. For severe infections, monitor clinical response and consider higher doses if needed.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Cephalothin is a first-generation cephalosporin with activity against gram-positive cocci (excluding MRSA and enterococci) and some gram-negative rods. It is often used perioperatively for surgical prophylaxis. Note that cephalothin is not active against Pseudomonas aeruginosa, Bacteroides fragilis, or Enterobacter species. Cross-allergenicity with penicillins occurs in approximately 5-10% of patients. Administer before meals if GI upset occurs. Monitor renal function in elderly or those with preexisting renal impairment, as cephalothin may accumulate and cause nephrotoxicity. Pain at injection site and phlebitis are common with IV administration.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
Take this medication exactly as prescribed, even if you feel well.,Complete the full course of therapy to prevent resistance.,Report any signs of allergic reaction such as rash, itching, swelling, or difficulty breathing immediately.,Inform your healthcare provider if you have a history of penicillin allergy.,If you experience severe diarrhea, especially with blood or mucus, contact your doctor (possible C. difficile colitis).,Use effective contraception during treatment, as cephalothin may reduce efficacy of oral contraceptives.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Cephalothin is a first-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in Gram-positive bacteria.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is: 1-2 g IV every 4-6 hours; maximum 12 g/day.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. Cephalothin is a first-generation cephalosporin classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal risk, and there are no adequate and . AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.